Streetbeat News

Price Targets

CBWBF

Credit Suisse analyst Han Joon Kim maintains a Neutral rating on Canadian Western Bank (OTC:CBWBF) and lowers the price target from C$26 to C$25.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 4:25 pm

DLR

Jefferies analyst Jonathan Petersen has reiterated a Buy rating on Digital Realty Trust (NYSE:DLR) and maintained a $129 price target.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 4:22 pm

SGCFF

RBC Capital analyst Darko Mihelic maintains an Outperform rating on Sagicor Financial (OTC:SGCFF) but lowers the price target from C$8 to C$6.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 4:20 pm

DLMAF

Scotiabank analyst George Doumet maintains an Outperform rating on Dollarama (OTC:DLMAF) and raises the price target from C$93 to C$95.5.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 4:13 pm

TRZBF

National Bank Financial Inc analyst Cameron Doerksen maintains an Underperform rating on Transat A.T. (OTC:TRZBF) and raises the price target from C$3 to C$3.25.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 4:10 pm

TRZBF

TD Securities analyst Tim James maintains a Hold rating on Transat A.T. (OTC:TRZBF) and raises the price target from C$4 to C$5.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 4:06 pm

JNJ

In the last 3 months, 6 analysts have offered 12-month price targets for Johnson & Johnson (NYSE:JNJ), with an average price target of $176.5, a decrease of 0.84% from the previous average of $178.00.

Portfolio Pulse from Benzinga Insights

May 30, 2023 | 4:04 pm

MDT

A whale investor has taken a bullish stance on Medtronic (NYSE: MDT), with 55% of detected trades having bullish expectations and 45% bearish. Whales have been targeting a price range of $70 to $92.5 for Medtronic over the last 3 months. Analysts from Truist Securities, Stifel, Bernstein, RBC Capital, and Evercore ISI Group have provided price targets ranging from $89 to $100.

Portfolio Pulse from Benzinga Insights

May 30, 2023 | 4:02 pm

SLRN

Morgan Stanley analyst Vikram Purohit initiates coverage on Acelyrin (NASDAQ:SLRN) with an Overweight rating and a price target of $29.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 3:59 pm

AKBA

HC Wainwright & Co. analyst Ed Arce reiterated a Neutral rating on Akebia Therapeutics (NASDAQ:AKBA) and maintained a $2 price target.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 3:56 pm